Align Technology stock steadies after Q2 2026 earnings as Invisalign demand supports outlook
Align Technology's stock is stabilizing after its Q2 2026 earnings report, which showed mid-single-digit revenue growth and stable margins, driven by strong demand for Invisalign clear aligners and digital orthodontic systems. Despite positive revenue trends, investor caution is influenced by management's slightly more conservative revenue outlook for the rest of 2026, leading to a consolidation phase for the shares. The company continues to invest in expanding its market for clear aligners and leveraging its digital workflow to offset macroeconomic pressures.
Align Technology Inc. stock underperforms Wednesday when compared to competitors
Align Technology Inc. (ALGN) shares dropped 2.90% to $163.04 on Wednesday, marking its third consecutive day of losses. This underperformance occurred despite a positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains.
Park State Asset Management Purchases New Holdings in Align Technology, Inc. $ALGN
Park State Asset Management has acquired a new stake in Align Technology, Inc. (NASDAQ:ALGN), purchasing 21,424 shares valued at approximately $3.61 million. This makes Align Technology the firm's 10th largest position, accounting for about 3.5% of its investment portfolio. Other institutional investors have also recently bought shares, with 88.43% of the stock currently owned by hedge funds and institutions.
Pallas Capital Advisors LLC Takes $1.13 Million Position in Align Technology, Inc. $ALGN
Pallas Capital Advisors LLC has acquired a new position in Align Technology, Inc. (NASDAQ:ALGN) by purchasing 6,689 shares valued at approximately $1.13 million during the second quarter. This move comes as institutional investors collectively own 88.43% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $206.36. Align Technology recently reported strong quarterly results, with revenues exceeding estimates and a new $200 million stock buyback program authorized.
K.J. Harrison & Partners Inc Acquires Shares of 11,100 Align Technology, Inc. $ALGN
K.J. Harrison & Partners Inc. recently acquired 11,100 shares of Align Technology, Inc. (NASDAQ:ALGN) valued at approximately $1.87 million during the second quarter. This move is part of broader institutional interest, with hedge funds and other institutional investors collectively owning 88.43% of the company. Align Technology reported strong quarterly earnings, beating analyst estimates, and authorized a $200 million stock buyback program.
Align Technology Inc (ALGN) Stock Down 5.6% -- Now Undervalued? GF Score: 89/100
Align Technology Inc (ALGN) experienced a 5.6% stock decline, bringing its price to $171.16, which GuruFocus assesses as undervalued with a GF Value™ estimate of $224.16. Despite a strong GF Score™ of 89/100, indicating solid fundamentals, insider selling totaling $1.5M over the past year without any buying activity suggests caution. Investors are advised to consider both the undervaluation and the insider sentiment when evaluating ALGN's potential.
ASU announces naming partner for football practice facility
Arizona State University has announced Align Technology as the naming rights partner for its new indoor football practice facility. The facility, to be called the Invisalign Performance Center, will break ground in the fall and is expected to open by spring 2028. This partnership builds on an existing relationship between ASU and Align Technology, which will support student-athletes and enhance the football program, including serving as a tailgating site on game days.
Align Technology makes transformational gift toward construction of indoor football practice facility
Align Technology, known for its Invisalign System, has made a significant naming rights gift to Arizona State University for the construction of the new Invisalign Performance Center, an indoor football practice facility. This "transformative" donation will provide Sun Devil Football with a state-of-the-art training ground, including a full 100-yard indoor field and a new volleyball practice facility, while also supporting student-athletes and enhancing game day experiences for fans. The partnership extends beyond the facility to include internships for ASU students and collaborative research initiatives, reinforcing Align Technology's community engagement and belief in ASU's vision.
Align Technology Inc. stock underperforms Monday when compared to competitors
Shares of Align Technology Inc. (ALGN) fell by 5.60% on Monday, closing at $171.16. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's drop ended a three-day winning streak.
NRX Pharmaceuticals earnings missed by $0.33, revenue fell short of estimates
NRX Pharmaceuticals (NASDAQ: NRXP) reported its second-quarter earnings, missing analyst estimates for both EPS and revenue. The company posted an EPS of $-0.440, significantly worse than the $-0.113 estimate, and revenue of $1.1M, falling short of the $1.75M consensus. Despite the miss, the stock has shown positive performance over the last 3 and 12 months.
How the U.K. VAT Ruling Could Reshape Align's 2026 Earnings Outlook
Align Technology (ALGN) is facing a new tax challenge in the U.K. following a July Upper Tribunal decision that overturned a VAT exemption for clear aligners, effective September 7, 2026. This ruling has resulted in an estimated $37.5 million liability for Align and adds a 20% VAT charge to its products in the U.K. without raising list prices. While the company plans to appeal, the issue is expected to further complicate its 2026 earnings outlook amidst existing pressures from foreign exchange rates and changing product mix, despite healthy international growth in clear aligner volume.
Cel-Sci shareholders elect directors and approve compensation plans at annual meeting
Cel-Sci Corporation shareholders elected directors Geert Kersten, Bruno Baillavoine, and Robert Watson at their annual meeting, along with approving the company's 2026 Non-Qualified Stock Option Plan and 2026 Stock Bonus Plan. Shareholders also ratified the appointment of BDO USA, LLP as the independent registered public accounting firm and approved executive officer compensation on a non-binding advisory basis. These decisions come as the company faces financial challenges, with its stock having significantly declined over the past year.
Align Technology: DCF Signals Overvaluation Despite Long-Term Growth Potential
Align Technology (ALGN) generated $1.06 billion in Q2 2026 revenue, with clear aligners seeing 8.2% growth, but systems and services declined. The company trades at a 16x forward P/E, significantly lower than a peer like Straumann due to weaker growth and less diversification. A discounted cash flow (DCF) model suggests a potential downside of 19.88% to 29.33% from the current market price of $181, even with bull case estimates falling below the current price, leading to a "hold" rating.
Align Technology, Inc. (ALGN) Stock Analysis: Unveiling a 15% Potential Upside in the Dynamic Medical Instruments Sector
Align Technology, Inc. (ALGN), known for Invisalign, shows a compelling investment case with a market cap of $12.88 billion and a 15.05% potential upside based on analyst targets. The company demonstrates financial resilience with a 4.30% revenue growth and strong free cash flow, reinvesting profits for expansion. Technical indicators signal a potential entry point despite the stock approaching oversold territory, and a largely positive analyst sentiment underscores confidence in its strategic direction and innovation.
Oppenheimer Asset Management Inc. Invests $1.20 Million in Align Technology, Inc. $ALGN
Oppenheimer Asset Management Inc. has invested $1.20 million in Align Technology, Inc. by purchasing 7,140 shares during the second quarter. Align Technology (NASDAQ:ALGN) reported strong quarterly earnings and revenue that exceeded expectations, alongside authorizing a $200 million share buyback. Analysts maintain a "Moderate Buy" consensus rating for the company, with an average price target of $206.36.
Align Technology, Inc. (NASDAQ:ALGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Align Technology, Inc. (NASDAQ:ALGN) has received a "Moderate Buy" consensus recommendation from 15 analysts, with an average 12-month price target of $206.36. This includes eight buy ratings, one strong buy, and six hold ratings. Recent positive analyst actions and the company's exceeding quarterly earnings expectations, along with a $200 million share-repurchase plan, underpin this optimistic outlook.
Align Technology (ALGN) Stock Looks Cheap On Cash Flow Yet Fair On Earnings
Align Technology's stock (ALGN) has seen a significant 73.4% decline over the past five years. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by about 41.6% based on projected cash flows, its P/E ratio of 31.1x indicates it's fairly valued compared to its industry and peers. The company's recent record revenue and share buyback program support potential cash flow growth, though competitive and legal risks remain.
9,838 Shares in Align Technology, Inc. $ALGN Acquired by Maridea Wealth Management LLC
Maridea Wealth Management LLC has acquired 9,838 shares of Align Technology, valued at approximately $1.66 million, as institutional investors continue to increase their holdings in the company. Align Technology recently reported strong quarterly earnings, surpassing EPS estimates, and announced a $200 million share-repurchase program. The stock has a "Moderate Buy" consensus rating from analysts, with an average price target of $206.36.
DENTSPLY Sirona Inc (XRAY) News, Articles, Events & Latest Updates
DENTSPLY Sirona Inc. (XRAY) reported a Q2 2026 profit, turning around from a loss in the previous year, driven by improved margins and the absence of prior impairment charges. Despite a 4.1% sales decline due to dental weakness, the company's Wellspect division showed growth, and its full-year 2026 guidance was reaffirmed. The article also includes various news items and earnings reports related to XRAY and other companies like Align Technology (ALGN), Envista (NVST), and McKesson (MCK).
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. (ALGN) saw its stock rise by 2.90% to $181.31, outperforming a generally down market where both the S&P 500 Index and Dow Jones Industrial Average experienced slight declines. This marked the third consecutive day of gains for the company's stock.
Should Investors Buy Align as Growth Meets Valuation and Demand Risks?
Align Technology (ALGN) presents a mixed investment case with strong international growth in Clear Aligner volumes and an expanding product portfolio, offset by soft North American retail demand and pressure from lower-priced scanners. While the stock's valuation offers some support, negative EPS growth projections and a weak Momentum Score suggest a cautious approach for investors. The company's Zacks Rank #3 (Hold) indicates patience is needed until clearer demand and earnings signals emerge.
A Dozen Universities Allotted Dentistry Research Grants From Align Technology
Align Technology Inc. has awarded 12 research grants to universities globally as part of its Fifteenth Annual Research Award Program. These grants support various dentistry topics, emphasizing Align's commitment to advancing scientific inquiry and innovation in orthodontics and dental care. The funded studies aim to deepen clinical understanding, inform treatment approaches, and ultimately enhance patient care worldwide.
Align Climbs to No. 1,572 on the 2026 Inc. 5000
Align, a global provider of technology infrastructure solutions and Managed IT Services, has been named to the 2026 Inc. 5000 list for the third consecutive year, ranking at No. 1,572. This marks a significant advancement from its previous rankings, driven by increased demand for its Data Center Solutions and expanding Managed Services, particularly within the financial services sector. The company attributes its continuous growth to adapting to market changes, understanding client needs, and expanding capabilities in areas like AI and infrastructure modernization.
Align Technology Inc. stock underperforms Thursday when compared to competitors despite daily gains
Align Technology Inc. (ALGN) stock increased by 1.26% on Thursday, closing at $176.20. Despite this daily gain, the stock underperformed compared to the broader market, as the S&P 500 rose 0.65% and the Dow Jones Industrial Average increased by 0.13%. This marks the second consecutive day of gains for Align Technology.
Align Technology Wins Patent Dispute Against Angelalign in China; Angelalign Plans to Appeal
Align Technology has won a patent infringement lawsuit against Angelalign Technology in China, with the Jinan Intermediate People’s Court ordering Angelalign to cease sales of certain products and pay RMB 10 million in damages. Angelalign plans to appeal the decision, asserting that its products do not infringe on any valid patent and that the ruling only applies in China with no immediate impact on customers. This ruling is part of ongoing global litigation between the two clear aligner manufacturers, which includes previous conflicting decisions in Germany and other Chinese courts.
Align Technology, Inc. (ALGN) Stock Forecasts
Argus has lowered its target price for Align Technology (ALGN), the leading manufacturer of clear aligners, to $194.00. The company's main product, Invisalign, holds over 90% of the market share. The current stock price for ALGN is $174.01.
Align Technology (ALGN): Capital World Investors reports 5% beneficial stake
Capital World Investors, a division of Capital Research and Management Company, has reported a beneficial ownership of 3,571,496 shares of Align Technology, Inc. common stock, which represents 5.0% of the company's outstanding shares. The filing indicates that Capital World Investors holds sole voting power over 3,550,442 shares and sole dispositive power over all 3,571,496 shares, with no shared voting or dispositive power. This Schedule 13G/A filing highlights a significant institutional stake in Align Technology.
Align Technology (ALGN) Gund-related holders report 5.4% beneficial stake
A group of trusts and individuals related to the Gund family have reported a collective beneficial ownership of 5.4% in Align Technology (ALGN), totaling 3,812,981 shares out of 71,039,852 outstanding shares as of July 31, 2026. Key figures in this group, G. Zachary Gund and Grant Gund, hold significant portions of these shares through various trusts and LLCs. The filing, an amended SCHEDULE 13G/A, details the individual holdings and their respective voting and dispositive powers.
Align says Chinese court ruled in its favour in Angelalign patent case
A Chinese court has issued a first-instance ruling in favor of Align Technology in its patent infringement case against Angelalign Technology. The court found that Angelalign infringed Align's patent related to closing extraction gaps using certain digital orthodontic treatment-planning technology and ordered Angelalign to cease using the technology, stop selling affected products, and pay 10 million yuan (C$2.1 million) in damages. The ruling is subject to appeal, and Align also faces a separate antitrust investigation by the European Commission regarding its Invisalign system.
Federal Circuit Clarifies Priority Requirements for Prior Art in Dental Monitoring SAS v. Align Technology
The Federal Circuit Court of Appeals clarified the requirements for a U.S. patent publication to serve as prior art based on a provisional application's filing date in *Dental Monitoring SAS v. Align Technology, Inc.* The court ruled that for a patent to claim priority from a provisional application, at least one claim in the reference patent must be supported by the provisional application, overturning the Patent Trial and Appeal Board's less stringent interpretation. The case has been remanded for further review to determine if the Carrier provisional application provides sufficient written description support.
Align Technology Wins China Patent Case Against Angelalign
Align Technology has won a patent infringement lawsuit in China against Angelalign Technology concerning extraction-gap-closure technology. The court ordered Angelalign to cease using the patented technology and manufacturing infringing products, also awarding Align RMB 10 million in damages. This ruling reinforces Align's commitment to protecting its intellectual property and innovation in the Chinese market.
1 Cash-Producing Stock Worth Your Attention and 2 That Underwhelm
This article identifies one strong cash-producing stock, Monolithic Power Systems (MPWR), that outperforms its competitors due to excellent revenue growth and profitability. Conversely, it highlights two underperforming companies, The Marzetti Company (MZTI) and Align Technology (ALGN), citing issues like muted revenue growth, stiff competition, and shrinking returns on capital as reasons to avoid them. The piece emphasizes the importance of effective cash allocation for investment success.
Align Technology Prevails in China Patent Infringement Action Against Angelalign
Align Technology announced that the Jinan Intermediate People's Court in China ruled in its favor in a patent infringement case against Angelalign Technology's operating subsidiaries. The court found Angelalign infringed Align's patent related to extraction-gap-closure technology, ordering them to cease using the technology and manufacturing infringing products in China, and awarded Align RMB 10 million in damages. This decision reinforces Align's intellectual property rights and follows other recent patent enforcement successes against Angelalign in Europe and the U.S.
Align Names Noel Kilcooley CTO to Lead AI and Technology Strategy
Align has appointed Noel Kilcooley as Chief Technology Officer, entrusting him with the company's technology strategy, AI initiatives, cybersecurity, and compliance. This move positions Align to support clients navigating complex infrastructure demands driven by AI adoption. Kilcooley, a 25-year veteran of the company, will leverage his expertise to integrate AI securely and efficiently within existing enterprise systems, reflecting a broader shift in the managed technology sector.
Contravisory Investment Management Inc. Makes New $1.11 Million Investment in Align Technology, Inc. $ALGN
Contravisory Investment Management Inc. recently invested $1.11 million in Align Technology (NASDAQ:ALGN) by acquiring 6,557 shares in the second quarter. This move is part of broader institutional interest, with hedge funds collectively owning 88.43% of the company. Align Technology has reported strong financial results, surpassing quarterly expectations with $2.64 EPS and $1.06 billion in revenue, and analysts maintain a "Moderate Buy" rating for the stock.
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. (ALGN) saw its stock rise by 1.37% to $176.04, outperforming a generally negative market day where the S&P 500 and Dow Jones Industrial Average both experienced declines. This marks the second consecutive day of gains for Align Technology.
Bank of America Corp DE Lowers Holdings in Align Technology, Inc. $ALGN
Bank of America Corp DE significantly reduced its stake in Align Technology, Inc. by 47.7% in the first quarter, selling 439,567 shares but still retaining 482,381 shares valued at $82.7 million. Despite this, Align Technology surpassed quarterly earnings and revenue expectations, reporting $2.64 adjusted EPS and $1.06 billion in revenue, leading the company to authorize a $200 million share repurchase program. Analysts maintain a "Moderate Buy" rating with an average price target of $206.36, indicating potential upside from its $173.66 opening price.
Did Align’s Expanded 2026 Buyback and Board Refresh Just Shift Align Technology's (ALGN) Investment Narrative?
Align Technology recently reported Q2 2026 results, showing increased sales but softer Q3 guidance and outlining impacts from restructuring and legal charges. In conjunction with Elliott Investment Management, Align committed to new board members, a strategic review, and an expanded 2026 share repurchase plan of US$400 million–US$500 million. This move highlights management's focus on capital allocation and governance, potentially shifting the investment narrative towards capital returns alongside growth in clear aligner volumes.
Did Align’s Expanded 2026 Buyback and Board Refresh Just Shift Align Technology's (ALGN) Investment Narrative?
Align Technology (ALGN) recently reported Q2 2026 results with increased sales but softer Q3 guidance, alongside restructuring and legal charges impacting margins. In response to discussions with Elliott Investment Management, Align committed to appointing three new independent directors, initiating a strategic review, and increasing its 2026 share repurchase plan to $400-$500 million. This expanded buyback commitment is seen as a significant development, potentially shifting Align's investment narrative by emphasizing capital returns alongside clear aligner volume and mix improvements, despite ongoing near-term demand and margin pressures.
Align Technology, Inc. $ALGN Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in Align Technology, Inc. (NASDAQ:ALGN) by 36.2% in the second quarter, selling over 358,000 shares. Despite this, other institutional investors like Capital International Investors and Invesco Ltd. increased their holdings. Align Technology reported strong Q2 earnings, beating analyst estimates, and announced a $200 million share repurchase program, indicating management believes the stock is undervalued.
Janus Henderson Group PLC Has $5.28 Million Holdings in Align Technology, Inc. $ALGN
Janus Henderson Group PLC reduced its stake in Align Technology, Inc. by 25.4% in the first quarter, now holding 30,791 shares valued at $5.28 million. Align Technology exceeded Q1 earnings expectations, reporting $2.64 EPS and $1.06 billion in revenue, and has a "Moderate Buy" consensus rating from analysts with a $206.36 price target. The company also authorized a $200 million share-repurchase program.
Align Technology, Inc. (ALGN) Stock Forecasts
Align Technology, Inc. (ALGN) is the leading manufacturer of clear aligners with its product, Invisalign, dominating over 90% of the market. Argus has lowered its target price for ALGN to $195.00, while the current price stands at $173.66.
Align Technology Inc. stock outperforms competitors on strong trading day
Align Technology Inc. (ALGN) saw its stock price increase by 2.71% to $173.66 on a strong trading day for the broader market, outperforming the S&P 500 and Dow Jones Industrial Average. Despite this gain, the company's stock closed 13.36% below its 52-week high.
Align Technology Expanding its Global Operations
Align Technology announced plans to open its first manufacturing facility in Hyderabad, India, by next year. This expansion, involving a $200 million investment and creating over 300 jobs, aims to bring operations closer to high-growth markets like India and enhance supply chain resilience. The facility, expected to be operational in 2027, will strengthen Align's global manufacturing network and support the growing adoption of its Invisalign System in the Asia-Pacific region.
Align Technology, Inc. (ALGN) Stock forecasts
Align Technology (ALGN) is the leading manufacturer of clear aligners, with its Invisalign product dominating over 90% of the market since its 1998 FDA approval. The company recently reported mixed earnings, where better-than-expected case volume was offset by weak scanner sales. The stock currently trades at $169.78.
Align Technology Inc (ALGN) Stock Down 3.2% -- Now Undervalued? GF Score: 89/100
Align Technology Inc (ALGN) shares recently dropped by 3.2%, bringing its current price to $169.08. Despite this, the stock is considered undervalued with a GF Value™ estimate of $228.51, and boasts a strong GF Score™ of 89/100, indicating robust fundamentals. While profitability and valuation are strong, growth scores are slightly lower, and mixed sentiment among gurus suggests investors should conduct further analysis.
Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Reports Q2 Revenue $898.0M, vs. FactSet Est of $889.9M
DENTSPLY SIRONA Inc. (XRAY) reported its Q2 revenue at $898.0 million, surpassing FactSet's estimate of $889.9 million. The company is a diversified manufacturer of professional dental products and technologies, offering comprehensive solutions across various dental segments. The report also highlights recent company news, including its Q2 2026 earnings call and adjusted EPS.
Align Technology Inc. stock underperforms Thursday when compared to competitors
Align Technology Inc. (ALGN) stock declined by 3.29% to $169.08 on Thursday, underperforming the broader market. This drop occurred during a session where the S&P 500 Index fell 0.18% and the Dow Jones Industrial Average dropped 0.85%, ending a three-day winning streak for the company's shares.
Quidelortho Corp (QDEL) News, Articles, Events & Latest Updates
This article provides recent news and updates for QuidelOrtho Corp (QDEL), highlighting its strong Q2 2026 earnings and revenue performance, which surpassed analyst estimates. It also includes details about the company's financial results, upcoming earnings reports, and an article discussing the changing landscape of the drug crisis, featuring QuidelOrtho's involvement. Additionally, it mentions QuidelOrtho's stock as a potential addition to portfolios due to its strong product portfolio and cost-saving efforts.
Align Technology (NASDAQ: ALGN) balances VAT hit with $200M India plant plan
Align Technology reported Q2 2026 net revenues of $1,056.2 million, up 4.3% year-over-year, driven by strong Clear Aligner revenues. The company also announced plans to invest $200 million in a new manufacturing facility in Hyderabad, India, expected to commence operations in 2027. This expansion aims to support growth, enhance supply chain resilience, and increase manufacturing capacity, balancing an estimated $37.5 million UK VAT liability following an adverse tribunal decision.
